Analysts have clear opinions on SUPN.
Based on 4 analysts offering 12 month price targets for SUPN in the last 3 months. The average price target is $52.50 with a high estimate of $59.00 and a low estimate of $46.00.
Supernus Pharmaceuticals, Inc. (SUPN) is followed by 4 analysts on the street. Their average price target to be reached in the next 12 months has a 104.52%Upside the most recent price.
David Steinberg from Jefferies rates it a Buy with a target of $46.00.
Similarly, 2 months ago Annabel Samimy of Stifel Nicolaus Reiterated a Buy with a target of $55.00.
The consensus on the street is Strong Buy.
What does Supernus Pharmaceuticals, Inc.(SUPN) do ?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The fir
Supernus Pharmaceuticals, Inc.(SUPN) Insider Trades
Multiple company employees have indulged in significant insider trading. Supernus Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that:
Pres, CEO, Khattar Jack A. : P – Purchase(+$189,982) of SUPN in the trading session of 2019-08-23.
SVP, CFO Patrick Gregory S : S – Sale+OE(-$830,650) of SUPN in the trading session of 2019-02-27.
VP, CFO Patrick Gregory S : S – Sale+OE(-$1,981,914) of Supernus Pharmaceuticals, Inc. in the trading session of 2018-07-02.